Literature DB >> 1745342

Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank.

A R Massaro1, R L Sacco, J P Mohr, M A Foulkes, T K Tatemichi, T R Price, D B Hier, P A Wolf.   

Abstract

Of the 1,805 patients with acute stroke enrolled in the Stroke Data Bank, 237 had parenchymatous hemorrhage. After excluding 34 secondary intracerebral and 31 infratentorial hemorrhage patients, a logistic regression analysis of the 172 patients with primary supratentorial intracerebral hemorrhage (ICH) elucidated clinical factors that distinguished the 65 patients with lobar hemorrhage (LH) from the 107 patients with deep hemorrhage (DH) located in the basal ganglia and thalamus. In LH, severe headache was more common than in DH, while hypertension and motor deficit were significantly less common. Patients with either LH or DH had a similar prognosis and mean Glasgow Coma Scale (GCS) scores, despite the hematoma volume measured on the initial CT being significantly greater for LH than DH. The presence of intraventricular extension (IVH) was more frequent in DH. The frequency of IVH increased with hematoma volume in LH, but remained constant for DH. Two CT variables (IVH and hematoma volume) that differed in these two hemorrhage groups were important predictors of coma (GCS less than or equal to 8) in a logistic regression model. Differences in the frequency of IVH may help explain why the degree of impairment in consciousness was similar in the two groups. Among patients with supratentorial ICH, location of the hematoma is related to both volume and IVH, which are important determinants of the level of consciousness.

Entities:  

Mesh:

Year:  1991        PMID: 1745342     DOI: 10.1212/wnl.41.12.1881

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Intracerebral Hemorrhage.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 2.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

3.  Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy.

Authors:  D T Winkler; L Bondolfi; M C Herzig; L Jann; M E Calhoun; K H Wiederhold; M Tolnay; M Staufenbiel; M Jucker
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

4.  Is hypertension a more frequent risk factor for deep than for lobar supratentorial intracerebral haemorrhage?

Authors:  C A Jackson; C L M Sudlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-11       Impact factor: 10.154

Review 5.  Alzheimer's silent partner: cerebral amyloid angiopathy.

Authors:  Tanya L Cupino; Matthew K Zabel
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

6.  Brain microhemorrhages detected on T2*-weighted gradient-echo MR images.

Authors:  Yoshito Tsushima; Jun Aoki; Keigo Endo
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

7.  Warfarin use leads to larger intracerebral hematomas.

Authors:  M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

Review 8.  Management of intracerebral hemorrhage.

Authors:  Mahmut Edip Gurol; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

9.  Comparative analysis of the spatial distribution and severity of cerebral microbleeds and old lacunes.

Authors:  S-H Lee; H-J Bae; S-B Ko; H Kim; B-W Yoon; J-K Roh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

Review 10.  Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.

Authors:  Eric E Smith; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.